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We studied 263 cases of Guillain-Barré syndrome from
1996 to 2001, 40% of which were associated with a known
causative agent, mainly Campylobacter jejuni (22%) or
cytomegalovirus (15%). The cases with no known agent
(60%) peaked in winter, and half were preceded by respira-
tory infection, influenzalike syndrome, or gastrointestinal
illness.
G
uillain-Barré syndrome (GBS) is a state of acute flac-
cid paralysis thought, in most cases, to result from an
aberrant immune response triggered by microbial infec-
tions (1). Studies in Western countries have reported evi-
dence of recent infection with Campylobacter jejuni in 15%
to 40% of GBS cases and with cytomegalovirus (CMV) in
5% to 20% of cases (1–5). Recent infection with Epstein-
Barr virus (EBV) or Mycoplasma pneumoniae was less fre-
quent (1%–2% each) (1–5). No agent was identified in 60%
to 70% of cases, although the patients often had a history of
respiratory or gastrointestinal infection (1,2).
Previous studies have failed to identify any clear season-
al distribution of GBS cases in Europe and North America.
It has been suggested that this failure to demonstrate sea-
sonality in GBS is because most prevalent antecedent infec-
tions have inverse seasonal distributions (6). We tested this
hypothesis to provide new insight into infectious agents
associated with GBS in Western countries.
The Study
All GBS patients admitted to the medical intensive care
unit of Raymond Poincaré Hospital in Garches, France,
from January 1996 to December 2001 were included in the
study. GBS was diagnosed according to the criteria of
Asbury and Cornblath (7). The following data were col-
lected at the time of hospital admission: time from onset of
neurologic signs of GBS to admission; history of infec-
tions in the 2 months preceding the onset of neurologic
signs; and time from the infectious event to onset of neu-
rologic signs. 
Serum samples were collected at hospital admission.
Serum antibodies against C.  jejuni and  M.  pneumoniae
were assayed with complement fixation tests (Institut
Virion, Würzburg, Germany); cutoff titers (C. jejuni 20; M.
pneumoniae 80) were selected to give >95% specificity on
the basis of data provided by the manufacturer. Serum
samples were tested for immunoglobulin M (IgM) and IgG
antibodies to CMV with the miniVIDAS system
(bioMérieux, Marcy l’Etoile, France). IgG avidity was
measured in samples positive for IgM by using the
Enzygnost anti-CMV/IgG test (Dade Behring S.A., Paris
la Défense, France) and 8 mol/L urea. Recent CMV infec-
tion was identified by detection of IgM with IgG avidity
<35% (8). Serum antibodies against EBV were detected
with commercial dot blot tests (ImmunoDOTEBVMONO
M and G kits, GenBio, San Diego, CA, USA). Recent
EBV infection was identified by detecting IgM antibodies
to viral capsid antigen. IgM and IgG antibodies against
gangliosides GM1 and GM2 were identified by an enzyme
immunoassay (GanglioCombi, Bühlmann Laboratories
AG, Schönenbuch, Switzerland) and an immunodot blot
assay (9). 
Statistical analyses were performed with the R 2.0.1
statistical package (R Development Core Team, Vienna,
Austria). Groups were compared in pairs, and the
Hochberg method for multiple testing was used to correct
p values (10). Categorical variables were compared by
Fisher exact test, and continuous variables were compared
by Student t test or Wilcoxon rank sum test. Seasonal
trends for GBS cases were analyzed by using the method
of Jones et al. (11). The number of harmonics (seasonality
periods) was determined by using the Akaike information
criterion. All tests were 2-tailed, and a p value <0.05 was
considered significant. 
During the study period, 279 consecutive patients with
GBS were admitted to our center. Sixteen patients were
excluded because of missing clinical data or serum sam-
ples; 263 were included in the study. On the basis of an
annual incidence of 1.2 to 1.9 GBS cases per 100,000 per-
sons (12) in a population of 10.952 million people (13), we
estimated that 130–210 GBS cases occurred annually in the
greater Paris area during the study period. Thus, this study
included 20%–30% of all estimated GBS cases in this area.
We observed serologic evidence of recent infection
with C. jejuni in 58 patients (21.9%), CMV in 40 (15.1%)
patients, M. pneumoniae in 6 (2.3%) patients, and EBV in
3 (1.15%) patients. Recent infection with C. jejuni and
CMV was observed in 1 patient. Thus, 106 cases (40%)
had >1 known agent of GBS (known agent group), and 157
cases (60%) had no known agent (unknown agent group)
(Table). Most patients in the C. jejuni group were male,
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ness (Figure 1), and exhibited a severe motor form of GBS
with serum IgG antibodies against ganglioside GM1.
Patients in the CMV group were significantly younger
(p<0.0001), more likely to have respiratory or influenza-
like symptoms than gastrointestinal symptoms (p<0.0001)
before the onset of GBS symptoms (Figure 1), and showed
a longer time from first neurologic signs to hospital admis-
sion (p = 0.048). These patients rarely showed a pure
motor form of GBS (p = 0.037) and frequently had IgM
antibodies against GM2 but did not have IgG antibodies
against GM1 (p<0.0001).
Patients in the unknown agent group were older than
those in the CMV group (p<0.0001), less likely to have
had a history of infectious events than patients in the C.
jejuni group (p = 0.0048), and had a significantly different
antiganglioside response than those in C. jejuni and CMV
groups (p<0.0001 in each case) (Table). The unknown
agent group had a higher proportion of patients with gas-
trointestinal illness than did the CMV group (p = 0.045)
and a higher proportion of patients with respiratory tract or
influenzalike symptoms than the C. jejuni group (p =
0.0024) (Figure 1).
No seasonal variation was found for all patients com-
bined (data not shown). However, this apparent absence of
variation masked a substantial seasonal difference for the
known agent and unknown agent groups. In the known
agent group, 60% of cases occurred in spring and summer;
only 16% occurred in winter. In the unknown agent group,
only 17% of cases occurred in summer; 37% occurred in
winter. 
We used the method of Jones et al. (11) to test the sea-
sonality of incidence. No seasonality was detected for the
groups all cases, known agent, and C. jejuni (Figure 2). For
the unknown agent group, a model with 1 harmonic
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Figure 1. Distribution of preceding infectious events in patients
with Guillain-Barré syndrome. ILS, influenzalike syndrome; URTI,
upper respiratory tract infection; LRTI, lower respiratory tract infec-
tion; GI, gastrointestinal illness; CMV, cytomegalovirus infection.
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(annual seasonality) gave a significantly better fit than a
model without harmonics (p = 0.0089, by likelihood ratio
test); additional harmonics did not improve the fit of the
model. Since no significant linear trend was found (p =
0.49), this element was removed for model prediction.
This best-fit, single-harmonic model indicated that inci-
dence was highest at the beginning of February and lowest
at the beginning of August (Figure 2).
Conclusions
This study provides new data about GBS patients not
associated with known etiologic agents, which account for
most patients in Western Europe (2,14). We have shown
that GBS cases of unknown cause were more common in
winter, with a peak incidence at the beginning of February.
Moreover, in ≈50% of the patients, GBS symptoms were
preceded by respiratory infection, influenzalike syndrome,
or gastrointestinal illness. Together with the seasonality of
cases, this finding suggests the involvement of winter
infectious agents, probably respiratory or enteric viruses.
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